Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 103
- 试验地点
- 10
- 主要终点
- Knowledge Assessed by Prostate Cancer Treatment Questionnaire
研究概览
简要总结
This randomized phase III trial studies how well decision aids work in improving knowledge in patients with prostate cancer. Decision aids may improve patients' knowledge of their condition and options for treatment, and may also help when talking with their doctor.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patients must have prostate biopsy within 4 months prior to registration showing newly diagnosed prostate cancer, stage T1-3N0M0; in addition, patients must have: Gleason score 6-10
- •Prostate-specific antigen (PSA) < 50 ng/mL
- •Patients who have had a history of non-cutaneous malignancy in the previous 5 years are not eligible; exception: patients with history of non-melanoma skin cancer are eligible
- •Scheduled prostate cancer consultation to be the first consultation after diagnosis (i.e. not a second-opinion or a consultation following previous discussions of treatment options)
- •Patients may not be concurrently enrolled to another clinical trial for the treatment of cancer; co-enrollment to biospecimen studies is allowed
- •Patients with impaired decision-making capacity (such as with a diagnosis of dementia or memory loss) are not eligible for this study
- •Patients must be able to read and comprehend English; non-English-speaking patients may participate so long as an interpreter (e.g., family member, clinic staff, etc.) is present for consent, for the decision aid administration, and gathering of baseline and follow-up measures
排除标准
- 未提供
结局指标
主要结局
Knowledge Assessed by Prostate Cancer Treatment Questionnaire
时间窗: 12 months
The primary outcome, knowledge, will be assessed by a standardized questionnaire (i.e., Prostate Cancer Treatment Questionnaire) administered once, immediately after the clinical consultation while the patient is still at the study site. The number correct from this 12-item measure will be reduced to a proportion of total number correct. With 1.0 (12 out of 12 item average) being the best possible outcome and 0.0 (0 out of 12 item average) the worst possible outcome
次要结局
- Utilization as Determined by Chart Review(12 months)
- Decisional Quality as Measured by Decisional Regret Scale(12 months)
- Quality of Life Assessed by Questionnaire(12 months)
研究者
Jon C. Tilburt
Principal Investigator
Mayo Clinic